Last reviewed · How we verify

Luis Fernando Simoneti — Portfolio Competitive Intelligence Brief

Luis Fernando Simoneti pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ketoprofen and Omeprazole Ketoprofen and Omeprazole marketed NSAID + Proton pump inhibitor combination COX-1/COX-2 (ketoprofen); H+/K+-ATPase (omeprazole) Rheumatology / Pain Management / Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. EMS · 1 shared drug class
  2. Giovana Maria Weckwerth · 1 shared drug class
  3. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class
  4. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Luis Fernando Simoneti:

Cite this brief

Drug Landscape (2026). Luis Fernando Simoneti — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/luis-fernando-simoneti. Accessed 2026-05-16.

Related